Taxane

Phase 3Small molecule

Bristol-Myers Squibb

Taxane is one of 138 small molecule programs targeting Esophageal Adenocarcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

137

Competitors

Pipeline

Status by Indication[3][1]

Indication

Esophageal AdenocarcinomaActive, not recruiting

Breast CancerWithdrawn

Cervical CancerActive, not recruiting

Advanced or Metastatic Solid TumorsRecruiting

Esophageal AdenocarcinomaPreclinical

Active, not recruiting

Breast CancerPhase 3

Withdrawn

Cervical CancerPreclinical

Active, not recruiting

Advanced or Metastatic Solid TumorsPhase 2

Recruiting

Competition

Competitive Landscape

706 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Taxane

Bristol-Myers Squibb

Phase 3

7 2

Adenocard

Astellas

Preclinical

2 3

Lexiscan

Astellas

Preclinical

1 4

Voltaren

Novartis

Preclinical

1 5

Zolymbus

AbbVie

Preclinical

1 6

Blenoxane

Bristol-Myers Squibb

Preclinical

1 7

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 8

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 9

Duragesic-100

CCephalon

Preclinical

2 10

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1/2Recruiting

Advanced or Metastatic Solid Tumors

NCT07158918

Q2 2028

Phase 2Recruiting

Breast Cancer

NCT06102824

Q4 2029

Phase 3Active, not recruiting

Breast Cancer; HER2-Positive; Metastatic

NCT04784715

Q4 2032

Phase 2Not yet recruiting

Breast Cancer

NCT07716046

Clinical

Trials by Indication[1]

Breast Cancer7 trials

Organoid-based Functional Precision Therapy for Advanced Breast Cancer

Recruiting·GGuangdong Provincial People's Hospital·Phase 2·NCT06102824·252 enrolled

Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients

Active, not recruiting·SSpanish Breast Cancer Research Group·Phase 2·NCT04293393·200 enrolled

Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer

Withdrawn·PPeregrine Pharmaceuticals·Phase 2/3·NCT02651610

Show 4 more trials

A Study of Neoadjuvant Paclitaxel in Combination With Bavituximab in Early- Stage Triple- Negative Breast Cancer

Withdrawn·PPeregrine Pharmaceuticals·Phase 2·NCT02685306

Carboplatin in EARLY Triple Negative Breast Cancer Trial (PEARLY Trial)

Active, not recruiting·YYonsei University·Phase 3·NCT02441933·878 enrolled

A Study of Herceptin (Trastuzumab) in Women With Metastatic Breast Cancer

Completed· Roche logo

Roche·Phase 2·NCT00475670·44 enrolled

Efficacy and Safety of Fulvestaciclib Combined With Anti-HER2 and Endocrine Therapy for First-line Maintenance or Upfront Chemo-Free Treatment in HR+/HER2+ Advanced Breast Cancer: A Multicenter, Open-label, Randomized Controlled Phase II Study

Not yet recruiting·FFudan University·Phase 2·NCT07716046·240 enrolled

Ovarian Cancer2 trials

Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse

Terminated·MMorphotek·Phase 3·NCT00849667·1,100 enrolled

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

Completed·EEpicentRx, Inc.·Phase 2·NCT02489903·139 enrolled

Advanced Cancer2 trials

A Phase I Study of a Single Dose of Radio-labeled BMS-275183 in Patients With Advanced Cancer

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT00326131·6 enrolled

A Phase I Study of BMS-275183 (Oral Taxane) Given on a Daily Schedule in Combination With Esomeprazole (Nexium) in Patients With Advanced Cancer

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT00332748·36 enrolled

Randomized1 trial

A Phase III Randomized Trial Assessing the Utility of a Test Dose Program With Taxanes

Completed·NNew Mexico Cancer Research Alliance·Phase 3·NCT00277043·200 enrolled

Biomarkers1 trial

Pharmacodynamic Biomarkers of Standard Anti-microtubule Drugs as Assessed by Early Tumor Biopsy

Terminated·UUniversity of Wisconsin, Madison··NCT03393741·5 enrolled

7 more indications

Lymphoma1 trial

Evaluation of Bay 59-8862 in Patients With Aggressive, Refractory Non-Hodgkin's Lymphoma

Completed· Bayer logo

Bayer·Phase 2·NCT00044551·29 enrolled

Non-Small Cell Lung Cancer1 trial

Oral Taxane in Combination With Pemetrexed (Alimta) in Patients With Recurrent Non-Small Cell Lung Cancer

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT00103831

Esophageal Adenocarcinoma1 trial

Interest of the Addition of Docetaxel to Standard Treatment in First-line Advanced HER2 Positive Gastroesophageal Adenocarcinoma in Selective Patients

Completed·—··NCT04920747·65 enrolled

Gastric Cancer1 trial

A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer

Terminated· Roche logo

Roche·Phase 2/3·NCT01641939·415 enrolled

Cervical Cancer1 trial

Prospective Study of Fertility-sparing Treatment Strategy in Patients With Early Cervical Cancer(SYSUGO-005/CSEM009)

Unknown status·SSun Yat-sen University·N/A·NCT02624531·60 enrolled

Advanced or Metastatic Solid Tumors1 trial

ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors

Recruiting·AABL Bio, Inc.·Phase 1/2·NCT07158918·65 enrolled

Breast Cancer; HER2-positive; Metastatic1 trial

Phase III Study of Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive, First-line Metastatic Breast Cancer (DESTINY-Breast09)

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT04784715·1,157 enrolled

Sources

References

[1]
ClinicalTrials.gov — 20 trial records for Taxane. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Taxane compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Taxane. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bristol-Myers Squibb company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Bristol-Myers Squibb

Taxane

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q2 2028

Q4 2029

Q4 2032

Trials by Indication[1]

Breast Cancer7 trials

Ovarian Cancer2 trials

Advanced Cancer2 trials

Randomized1 trial

Biomarkers1 trial

Lymphoma1 trial

Non-Small Cell Lung Cancer1 trial

Esophageal Adenocarcinoma1 trial

Gastric Cancer1 trial

Cervical Cancer1 trial

Advanced or Metastatic Solid Tumors1 trial

Breast Cancer; HER2-positive; Metastatic1 trial

References

Drug Info

Quick Facts

Related News